tbuckley/cabot-search huggingface dataset:
MESOTHELIOMA OF THE PERITONEUM: A CASE REPORT IN WHICH THE ASCITIC FLUID CONTAINED HYALURONIC ACID
Authors: Samuel Dvoskin
Journal: Annals of Internal Medicine (1954)

Case Reports1 April 1954MESOTHELIOMA OF THE PERITONEUM: A CASE REPORT IN WHICH THE ASCITIC FLUID CONTAINED HYALURONIC ACIDSAMUEL DVOSKINSAMUEL DVOSKINSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-40-4-809 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptHyaluronic acid has been isolated from the pleural or peritoneal fluid associated with mesothelioma by Meyer and Chaffee1 and Blix.2 In our case this finding led to the suspicion of the diagnosis of mesothelioma, later confirmed by the autopsy findings.CASE REPORTA 27 year old white female was admitted to the United States Army Hospital, Fort McClellan, Alabama, on May 1, 1952, for repair of a left inguinal hernia. Convalescence was uneventful, and she was discharged on May 8. Several days after discharge from the hospital the patient noted that her abdomen was enlarging. On May 10 she developed...Bibliography1. MeyerChaffee KE: Hyaluronic acid in the pleural fluid associated with a malignant tumor involving the pleura and peritoneum, J. Biol. Chem. 133: 83-91, 1940. CrossrefGoogle Scholar2. Blix G: Hyaluronic acid in the pleural and peritoneal fluids from a case of mesothelioma, Acta Soc. Med. Upsal. 56: 47-50, 1951. MedlineGoogle Scholar3. Meyer K: Personal communication, 1952. Google Scholar4. Stout AP: Personal communication, 1952. Google Scholar5. Truedsson E: A case of mesothelioma of the pleura and peritoneum producing hyaluronic acid, Acta Soc. Med. Upsal. 56: 39-45, 1951. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication August 31, 1953. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byBenign papillary mesothelioma of peritoneum: a histological, histochemical and ultrastructural study of six casesClinical pathologic conferenceThe detection of hyaluronic acid in the serum and urine of a patient with nephroblastomaPrimary Malignant Mesothelioma of the PericardiumThe exfoliative cytology of diffuse malignant mesotheliomaMalignant peritoneal mesotheliomas.A clinicopathological analysis of 12 fatal casesMesotheliomas and extraovarian thecomas with hypoglycemic and nephrotic syndromesPeritoneal mesotheliomaProlonged survival in diffuse pleural mesothelioma treated with AU198Malignant, diffuse mesothelioma of the pleuraAllgemeine Aspekte der LungenuntersuchungAllgemeine Symptomatologie der Lungen- und BronchialerkrankungenPrimary pericardial mesothelioma 1 April 1954Volume 40, Issue 4Page: 809-811KeywordsAutopsyConvalescenceHerniaMesotheliomaPeritoneum ePublished: 1 December 2008 Issue Published: 1 April 1954 PDF downloadLoading ...
Nutrition, Weight Control, and Exercise.
Authors: Frank I. Katch, William D. McArdle
Journal: Annals of Internal Medicine (1984)

The book is clearly written, and the electrocardiographic examples of the various rhythm disturbances are also clear and well described. Written primarily for medical students, house officers, and noncardiologist physicians, the book nonetheless serves as a useful review of arrhythmias for cardiologists or fellows in cardiology but would not be an adequate reference text for subspecialists in cardiology. The strongest features of this book are the electrocardiographs recordings, clearly displayed in a 12-lead format with 3-lead rhythm strips. Most books of this type include single-lead rhythm strips that do not clearly correlate with the descriptions of the various diagnostic criteria used to interpret rhythm abnormalities. The excellent illustrations in this book alleviate this difficulty in interpretation that is so common in texts that deal with arrhythmias.
Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group.
Authors: Gordon Murray
Journal: BMJ (1989)

To determine whether ketanserin, an antagonist at the serotonin receptor, prevents important vascular events such as death, myocardial infarction, major stroke, and amputation of a leg in patients with claudication.Double blind, randomised, placebo controlled trial after a single blind run in period of placebo treatment for one month.One hundred and forty seven outpatient clinics in 14 countries.Total of 3899 patients over 40 years old who had had documented intermittent claudication for at least two months and in whom the ratio of systolic blood pressure in the ankle to that in the arm was less than or equal to 0.85 in both arteries of at least one foot.After the one month placebo run in period patients were randomly allocated to take 20 mg ketanserin three times daily for the first month and 40 mg three times daily thereafter or to take the same number of placebo tablets. Five months after the onset of the trial, on the recommendation of the ethical and safety committee, four patients stopped taking ketanserin and two stopped taking placebo because they had a corrected QT interval greater than 500 ms. Four months later the committee recommended that all patients taking diuretics should stop receiving trial treatment (167 of those taking ketanserin and 144 of those taking placebo).The first primary event after randomisation. Primary events were definite myocardial infarction, major stroke, amputation above the ankle, excision of ischaemic viscera, and death due to other vascular causes.There were 136 study end points in the 1930 patients treated with ketanserin, who were followed up for 2063 patient years, and 132 study end points in the 1969 patients treated with placebo, who were followed up for 2129 patient years. A harmful interaction of ketanserin and potassium losing diuretics resulted in an increase in the number of deaths. After patients taking potassium losing diuretics or antiarrhythmic agents were excluded [corrected] a secondary analysis showed that there were 65 end points in 1514 patients taking ketanserin and 87 in 1557 patients taking placebo, a reduction of 23% in the number of study end points in those taking ketanserin.Ketanserin can prolong the corrected QT interval, and the combined use of ketanserin and potassium losing diuretics can be harmful. A secondary analysis suggested a protective effect of ketanserin against cardiovascular complications in patients with claudication.
Abstract 1990: Re-appraisal Of Interhospital Transfer For Primary Angioplasty In The Context Of An Effective Service With Rapid Institutional Door-balloon Times
Authors: Miles C Dalby, Rajesh K Kharbanda, Gopal Ghimire, Jonathan R Spiro, Michael Roughton, Mohammed Al-Obaidi, Rebecca Lane, Molly Teoh, Liz Hutchison, M Whitbread, Richard Grocott-Mason, Andrew Mitchell, Mark Mason, Charles Ilsley
Journal: Circulation (2007)

Objective: Primary Percutaneous Coronary Intervention (PPCI) is the preferred reperfusion therapy in ST elevation myocardial infarction. Guidelines recommend door-balloon time of < 90 minutes and a...
Abstract 17559: Ultra-Early Endothelialization of Biolimus A9 With Bioresorbable Polymer Stent (Nobori <sup>®</sup> ) in Porcine Coronary Model: Possible Mechanism for Low Frequency of In-stent Thrombosis and Restenosis
Authors: Masayuki Mori, Takuya Nakahashi, Shu Takabatake, Chiaki Nakanishi, Kenji Sakata, Hirofumi Okada, Shohei Yoshida, Kenshi Hayashi, Tsuyoshi Yoshimuta, Masa-aki Kawashiri, Takehisa Matsuda, Masakazu Yamagishi
Journal: Circulation (2014)

Background: The stent with biolimus A9 coated by a bioresorbable polymer (Nobori ® ) has the potential to reduce thrombosis by degradation of polymer over the period. However, few data exist regarding the vessel response and endothelialization at ultra-early phase after its implantation. Therefore, we examined ultra-early endothelialization of Nobori ® in porcine model. Methods and Results: Fifteen Nobori ® and 14 control bare-metal stents (S-Stent TM ) were implanted in 12 swine (mean weight 31.9 kg). Histopathological evaluation of stented segments were performed at 2 and 14 days after implantation. Morphometric analysis of the inflammation (graded as score 0 to 3) and the intimal fibrin content (graded as score 1 to 3) was also assessed. At 14 days, neointimal thickness and % neointimal area, defined as 100 х neointimal area / stent area, were significantly lower in Nobori ® than in S-Stent TM (51.4 ± 5.9 μm vs 76.4 ± 9.6 μm, p &lt; 0.05 and 11.2 ± 1.1 % vs 15.7 ± 1.3 %, p &lt; 0.01, respectively). Importantly, there were no significant differences in these parameters between 2 groups at 2 days (17.3 ± 6.1 μm vs 26.7 ± 6.1 μm, p = NS and 3.8 ± 1.3% vs 6.9 ± 1.7%, p = NS, respectively). Under these conditions, stent surface endothelialization evaluated by scanning electron microscope at 2 days showed similar appearance of endothelial coverage above the struts in Nobori ® compared with S-Stent TM (Figure). Furthermore, there were no significant differences in inflammatory (1.3 ± 0.1 vs 1.3 ± 0.1, p = NS) and intimal fibrin content (2.5 ± 0.1 vs 2.3 ± 0.1, p = NS) scores. Conclusion: These results demonstrated that endothelialization could occur at ultra-early phase after Nobori ® implantation with similar inflammatory reaction to bare-metal stent, probably contributing to low frequency of in-stent thrombosis and restenosis. The use of Nobori ® may have a potential benefit even at early phase before the degradation of polymer as well as long-term benefit.
Methodologic rigor of clinical trials on surgical management of eyes with coexisting cataract and glaucoma 1 1This article is based on research conducted by the Johns Hopkins University Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality (formerly the Agency for Health Care Policy and Research; contract no. 290-97-0006), Rockville, Maryland. The authors of this article are responsible for its contents, including any clinical or treatment …
Authors: Henry D Jampel, David S Friedman, Lisa H Lubomski, John H Kempen, Harry Quigley, Nathan Congdon, Hani Levkovitch-Verbin, Karen A Robinson, Eric B Bass
Journal: Ophthalmology (2002)
Genuine Hereditary Hydronephrosis in a Three-Generation Family Clinicopathological and Genetic Implications with a Review of the Literature
Authors: Pedro G. Páramo, L. Izquierdo, P Páramo, Jr., L. Llorente, A. Diego, A. Páez, J.J. Gômez Ruiz, A.C. Usón
Journal: European Urology (1991)
Abstract 3707: A Novel Role of the Sympatho-Adrenergic System in Regulating Valve Calcification
Authors: Lana Osman, Adrian H Chester, Patricia M Taylor, Yacoub H Magdi
Journal: Circulation (2006)

Aortic valve Calcification has been shown to be a progressive process resembling ossification. Recent evidence has indicated that the sympathetic nervous system plays an important role in regulatin...
Cancer Risk Fears From 9/11 Attack Eased
Authors: Mike Mitka
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effectiveness of skin cancer screening programmes
Authors: K. Choudhury, B. Volkmer, R. Greinert, E. Christophers, E.W. Breitbart
Journal: British Journal of Dermatology (2012)

Skin cancer, nonmelanoma skin cancer (NMSC) and cutaneous malignant melanoma (CMM), is the most frequent cancer worldwide. It is amenable to early detection, and screening for skin cancer has the potential to reduce mortality and morbidity. However, there are no recommendations for population-based skin cancer screening programmes due to the lack of evidence for the effectiveness from epidemiological studies. In 2008 the first nationwide screening programme for NMSC and CMM in the world was established in Germany. The decision for implementing such a programme was based on the results and evidence of a pilot study that was conducted from 2003 to 2004. The pilot study revealed that a population-based screening programme for skin cancer is feasible and effective. Careful evaluation of the nationwide programme is crucial to generate strong evidence for long-term public health benefits.
Abstract 11328: Plasma Chemerin is a Strong and Independent Predictor of Cardiovacular Event Risk
Authors: Andreas Leiherer, Axel Muendlein, Philipp Rein, Kathrin Geiger, Peter Fraunberger, Alexander Vonbank, Christoph H Saely, Heinz Drexel
Journal: Circulation (2014)

Introduction: Associations of the adipokine chemerin with the metabolic syndrome (MetS) and with chronic kidney disease (CKD), two important indicators of increased cardiovascular event risk, have been described. However, the power of chemerin to predict cardiovascular events has not been investigated so far and is addressed in the present study. Hypothesis: We hypothesized that high plasma chemerin is associated with an increased cardiovascular event risk. Methods: We measured plasma chemerin in a high-risk cohort of 495 patients undergoing coronary angiography for the evaluation of suspected or established coronary artery disease (CAD) in which cardiovascular events were prospectively recorded over 3.5±1.1 years. Significant baseline CAD was diagnosed in the presence of coronary artery stenoses ≥50%. Results: At baseline, plasma chemerin was significantly higher in patients with the MetS as defined by the current harmonized consensus definition (n=147) than in non-MetS subjects (201±71 ng/ml vs. 163±62 ng/ml p&lt;0.001) and was inversely correlated with estimated glomerular filtration rate (eGFR; r=-0.33, p&lt;0.001). During follow-up, chemerin significantly predicted cardiovascular events (n=82) univariately, after adjustment for age, gender, BMI, and eGFR, and also after additional adjustment for the presence of significant baseline CAD, with standardized hazard ratios of 1.83 [1.19-2.83], p= 0.006; 1.77 [1.12-2.80], p =0.015; and 1.69 [1.07-2.67], p=0.024, respectively. Conclusions: From this first prospective evaluation of the cardiovascular event risk associated with chemerin we conclude that chemerin is strongly predictive of cardiovascular events independently from standard risk factors, from the MetS, and from the baseline presence of CAD.
Two major problems in TB patients today: MDR and the abandoned therapy
Authors: Gabriela Barbulescu, Laurentia Badulescu
Journal: European Respiratory Journal (2011)

In the WHO strategy, “stop TB” is the ultimate goal in the fight against this extended infectious disease. However, despite this ambitious purpose and the tools developed in this matter, some impediments may occur.   Aims:  In this paper, the authors proposed to emphasize the latest and striking observations on difficulties encountered in TB treatment, in a pneumology department.   Methods:  We observed the TB cases admitted in our service in 2010 compared with 2009 and noted the chronics, relapse cases. We noted why these patients couldn9t rich to a proper end of their treatment and be cured. Equally, we were interesed in number of MDR cases admitted in both years, comparative.   Results:  All TB patients evaluated in 2010 were 456. From these, 255 were chronics, developping at least a third treatment (by failed or abandoned treatment). From these ones, 12 patients were with secondary MDR (5 of them with additional resistance to SM or EMB). Besides, we had 2 patients with XDR. In 2009 we had 468 TB patients, from which 214 were chronics, 165 abandoning their schedule and coming to hospital in 2010. In 2009 we noted just 5 patients with MDR. It is worthing noting the lack of secondary aminoglicosides like Kanamicine and Amikacine and the imposibility of admitting all these patients in the unique service of MDR in town.   Conclusions:  We are worried about the increase of number of cases with treatment abandon and the MDR cases. There is an important number of patients who cannot be compelled to folow the treatment when they leave the hospital (because of different reasons: social, tolerance, first treatment failed). Isolation of MDR cases from other TB patients in the same hospital seems difficult.
Secrets of the “Great Mimicker”
Authors: Joan Stephenson
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cope's Early Diagnosis of the Acute Abdomen.
Authors: William Silen
Journal: Annals of Internal Medicine (1979)

1. The principles of diagnosis in acute abdominal disease 2. Method of diagnosis: the history 3. Method of diagnosis: the examination of the patient 4. Method of diagnosis: the grouping of symptoms and signs 5. Laboratory and radiological tests 6. Appendicitis 7. The differential diagnosis of appendicitis 8. Perforation of a gastric or duodenal ulcer 9. Acute pancreatitis 10. Cholecystitis and other causes of acute pain in the right upper quadrant of the abdomen 11. Acute abdominal lesions arising in the left hypochondrium 12. The colics 13. Acute intestinal obstruction 14. Intussusception and other causes of obstruction 15. The early diagnosis of strangulated and obstructed hernias 16. Acute abdominal symptoms due to vascular lesions 17. Acute abdominal symptoms in women 18. Early ectopic gestation 19. Acute abdominal disease with genitourinary symptoms 20. The diagnosis of acute peritonitis 21. The early diagnosis of abdominal injuries 22. The postoperative abdomen 23. The acute abdomen in the tropics 24. Diseases that may simulate the acute abdomen 25. Acute abdominal pain in the immunocompromised patient 26. Abdominal catastrophes when sensation is impaired
Abstract P4-05-09: Matrin 3: A novel micro-tubule associated RNA binding protein that acts as a potent tumor suppressor
Authors: Panneerdoss Subbarayalu, Subapriya Rajamanickam, Suryavathi Viswanadhapalli, Nicholas Dybdal-Hargreaves, Santosh Timilsina, Sanjay Bansal, Hima Bansal, Tabrez Mohammad, Yidong Chen, John C Herr, Susan L Mooberry, Manjeet K Rao
Journal: Cancer Research (2015)

Abstract Microtubules are highly dynamic components of the cytoskeleton that play an important role in a wide range of cellular processes including cell division, cell motility and intracellular transport. Increasing evidence suggests that alterations in microtubule dynamics are critical for cancer growth and metastasis. Microtubule associated proteins (MAPs) regulate microtubule dynamics and consequently can affect sensitivity of cancer cells to microtubule targeting drugs. We discovered a novel microtubule associated protein "Matrin 3 (MATR3)" that is known to bind to RNA and play a critical role in RNA transport and RNA stabilization. Immunofluorescence analyses revealed that although MATR3 is predominantly a nuclear protein, it translocates to the cytoplasm and interacts with microtubules when breast cancer cells are treated with paclitaxel. We show that MATR3 associates with stabilized microtubules and it mediates microtubule polymerization in a taxol-dependent manner. Interestingly, our results reveal that MATR3 acts as a effective tumor suppressor as it inhibits breast cancer colony formation, migration and invasion of breast cancer cells in addition to suppressing breast tumor growth in vivo. Analysis of breast cancer samples showed a significantly lower expression of MATR3 when compared to normal adjacent tissues. Our results indicate the possibility that MATR3 mediates its tumor suppressor function by binding and regulating proteins that are known to affect microtubule dynamics. We believe that nuclear-cytoplasmic shuttling of MATR3 is critical for stability of key proteins that might regulate paclitaxel-dependent microtubule dynamics and subsequently cellular effects in cancer cells. Citation Format: Panneerdoss Subbarayalu, Subapriya Rajamanickam, Suryavathi Viswanadhapalli, Nicholas Dybdal-Hargreaves, Santosh Timilsina, Sanjay Bansal, Hima Bansal, Tabrez Mohammad, Yidong Chen, John C Herr, Susan L Mooberry, Manjeet K Rao. Matrin 3: A novel micro-tubule associated RNA binding protein that acts as a potent tumor suppressor [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P4-05-09.